Sign inJoin waitlistJoin the waitlist

Anjalika Gandhi

Clinical Assistant Professor · University of Toledo

Credentials: · · · · · ·

History

University of Toledo
Present

Gynecologic Oncology
University of Oklahoma Health Sciences Center
2019–2022
Obstetrics and Gynecology
University of South Florida Morsani College of Medicine
2015–2019
Cleveland Clinic Lerner College of Medicine
2011–2015

Research

Determining the fertility benefit of controlled ovarian hyperstimulation with intrauterine insemination after operative laparoscopy in patients with endometriosis
Journal of Minimally Invasive Gynecology · 2014 · First of 4 authors · 13 citations
Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center
Clinical Genetics · 2020 · 9 citations
Does supraphysiologic estradiol level during IVF have any effect on oocyte/embryo quality? A sibling embryo cohort analysis of fresh and subsequent frozen embryo transfer
Minerva Ginecologica · 2018 · 9 citations

AM
Adrianne Mallen
1 paper · 1 as a fellow
AW
Ali Wells
1 paper
Anthony Imudia
1 paper
BB
Bernadette Boac
1 paper · 1 as a resident
JM
James Mayer
1 paper
Katherine Moxley
1 paper
Michelle Kuznicki
1 paper · 1 as a fellow
PS
Papri Sarkar
1 paper · 1 as a resident
Robert Wenham
1 paper
ST
Sarah Todd
1 paper · 1 as a fellow
Shayne Plosker
1 paper
Tommaso Falcone
1 paper

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Letrozole in Uterine Leiomyosarcoma
Site PI · Recruiting · Phase 2
GOG Foundation
2024–2029